Leukoregulin Enhancement of Tumor Inhibitory Drug Uptake

  • C. H. Evans
  • P. D. Baker
Conference paper

Abstract

Leukoregulin is a 32 kDa glycoprotein cytokine secreted by lymphocytes and monocytes which possesses unique regulatory activities for tumor cells and for cells undergoing transformation to the neoplastic state [1, 2]. These anticancer actions include (a) prevention of chemical carcinogen and radiation-induced transformation, (b) inhibition of neoplastic cell proliferation, (c) increased plasma membrane permeability associated with enhancement of target cell sensitivity to natural killer cell cytotoxicity, and (d) lysis of neoplastic cells.

Keywords

Permeability High Performance Liquid Chromatography Lymphoma Adenosine Electrophoresis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ransom JH, Evans CH, McCabe RP, Pomato N, Heinbaugh JA, Chin M, Hanna MG Jr (1985) Leukoregulin, a direct-acting anti-cancer immunologic hormone that is distinct from lymphotoxin and interferon. Cancer Res 45:851–862PubMedGoogle Scholar
  2. 2.
    Evans CH (1988) Mechanisms of leukoregulin anti-cancer action. In:Ransom JH, Ortaldo J (eds) Leukolysins and cancer:biological and chemical Aspects Humana, Clifton, pp 198–216Google Scholar
  3. 3.
    Evans CH, Ransom JH (1984) The anti-cancer action of lymphotoxin. In:Goldstein AL (ed) Thymic hormones and lymphokines Plenum, New York, pp 357–364Google Scholar
  4. 4.
    Cleveland L, Ransom JH, Evans CH (1984). Leukoregulin, a new anticancer lymphokine distinct from lymphotoxin and interferon. Fed Proc 43:1931Google Scholar
  5. 5.
    Evans CH (1984) Rapid flow cytometric quantitation of leukoregulin, the dominant direct acting anti-tumor lymphokine in lymphotoxin preparations. Fed Proc 43:1970Google Scholar
  6. 6.
    Evans CH (1982) Lymphotoxin — an immunologic hormone with anticarcinogen and antitumor activity. Cancer Immunol Immunother 12:181–190CrossRefGoogle Scholar
  7. 7.
    Barnett SC, Evans CH (1986) Leukoregulin increased plasma membrane permeability and associated ionic fluxes. Cancer Res 46:2686–2692PubMedGoogle Scholar
  8. 8.
    Evans CH, Wilson AC, Gelleri BA (1989). Preparative isoelectric focusing in ampholine electrofocusing columns versus immobiline polyacrylamide gel for the purification of biologically active leukoregulin. Anal Biochem 177:358–363PubMedCrossRefGoogle Scholar
  9. 9.
    Evans CH, Heinbaugh JA, Ransom JH (1987) Flow cytometric evaluation of leukoregulin as an intrinsic molecular mediator of natural killer lymphocyte cytotoxicity. Lymphokine Res 6:277–297PubMedGoogle Scholar
  10. 10.
    Ransom JH, Evans CH (1982) Lymphotoxin enhances the susceptibility of neoplastic and preneoplastic cells to natural killer cell mediated destruction. Int J Cancer 29:451–458PubMedCrossRefGoogle Scholar
  11. 11.
    Furbert-Harris P, Evans CH (1989) Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity. Cancer Immunol Immunother 30:1314–1317CrossRefGoogle Scholar
  12. 12.
    Trinchieri G, Santoli D (1978) Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med 147:1314–1317PubMedCrossRefGoogle Scholar
  13. 13.
    Ortaldo JR, Ransom JH, Herberman RB, Sayres TJ (1986). Analysis of cytostatic/cytotoxic lymphokines:relationship of natural killer cytotoxic factor to recombinant lymphotoxin, recombinant tumor necrosis factor, and leukoregulin. J Immunol 137:2857–2863PubMedGoogle Scholar
  14. 14.
    Merchant RE, Ransom JH, Young HF (1986) Leukoregulin inhibits the growth of human glioblastoma in vitro. J Neuroimmunol 13:31–45PubMedCrossRefGoogle Scholar
  15. 15.
    Sheehy PA, Barnett SC, Evans CH, Barker JL (1988). Activation of ion channels in tumor cells by leukoregulin, a cytostatic lymphokine. JNCI 80:868–871PubMedGoogle Scholar
  16. 16.
    Barnett SC, Evans CH (1988) Leukoregulin induced translocation of protein kinase C activity in K562 cells. Clin Exp Immunol 73:505–509PubMedGoogle Scholar
  17. 17.
    Evans CH, Baker PD (1988) Tumor-inhibitory antibiotic uptake facilitated by leukoregulin:a new approach to drug delivery. JNCI 80:861–864PubMedGoogle Scholar

Copyright information

© Springer-Verlag, Berlin Heidelberg 1990

Authors and Affiliations

  • C. H. Evans
  • P. D. Baker

There are no affiliations available

Personalised recommendations